Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-08

Study Completion Date

2019-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and placebo); Part B: treatment period 3, is an open label extension to part A and starts after a washout of 6-10 weeks after the last dose in treatment period 2. patients are dosed once weekly for 4 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

NCT03408132

SBS - Short Bowel Syndrome

COMPLETED PHASE1/PHASE2

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

NCT01560403

Short Bowel Syndrome

COMPLETED PHASE3

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

NCT03562130

Short Bowel Syndrome

COMPLETED PHASE4

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025

Short Bowel Syndrome

COMPLETED PHASE3

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

NCT00742157

Short Bowel Syndrome

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is divided into 2 parts. Part A of this trial is a repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and PD of FE 203799 in 8-10 patients with SBS. Additionally, the plasma concentration of FE 203799 will be assessed for determination of the trough and post-dose concentration in SBS patients. The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 or placebo once weekly for 4 consecutive weeks, and after a washout period of 6-10 weeks, the alternate treatment will be administered once weekly for 4 consecutive weeks. Safety follow-up assessments will be performed 6-10 weeks after the last dose in each treatment period.

Part B of this trial, treatment period 3, is an open label extension to part A that will test a new dose. Following a washout period of 6-10 weeks after the last dose in treatment period 2, the new dose will be administered once weekly for 4 weeks. Safety follow-up assessments will be performed 4-6 weeks after the last dose in treatment period 3.

The first two administrations of trial drug in each treatment period will be performed at the clinic, while the third and fourth dose can be either self-administered by the patient or administered at the clinic if the patient prefers to travel to the site or other considerations make a site visit preferable.

Prior to each administration of trial drug, liver function parameters will be analysed and assessed. During each treatment period, patients who develop extremely high or persistently elevated liver enzymes following trial drug administration will be discontinued from the trial.

The patients will complete a diary during each treatment period with daily data on parenteral support (PS) usage, oral liquid intake at specific periods, trial drug administrations performed at home, local tolerability and adverse events (AEs).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Short Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FE203799 5 mg

FE203799 GLP-2 analogue, once weekly, subcutaneous administration

Group Type EXPERIMENTAL

FE203799 GLP-2 analogue

Intervention Type DRUG

FE203799 5 mg subQ once weekly

Placebo

Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration

Group Type PLACEBO_COMPARATOR

FE203799 Placebo GLP-2 analogue

Intervention Type DRUG

Placebo subQ once weekly

FE203799 10 mg

FE203799 GLP-2 analogue, once weekly, subcutaneous administration

Group Type OTHER

FE203799 GLP-2 analogue

Intervention Type DRUG

FE203799 10 mg subQ once weekly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FE203799 GLP-2 analogue

FE203799 5 mg subQ once weekly

Intervention Type DRUG

FE203799 Placebo GLP-2 analogue

Placebo subQ once weekly

Intervention Type DRUG

FE203799 GLP-2 analogue

FE203799 10 mg subQ once weekly

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females with SBS secondary to surgical resection of small intestine
2. 18-80 years of age
3. Body Mass Index (BMI) between 16.0 and 32.0
4. Patients with a jejuno- or ileostomy and a faecal wet weight excretion of at least 1500 g/day, as recorded within the last 18 months according to the patient's medical record
5. Parenteral support ≥3 times/week for ≥12 months according to the patient's medical record
6. At least 6 months since last surgical bowel resection
7. Willing to adhere to a defined oral intake of fluids on certain days as required by the protocol (and based on the individual's routine daily consumption)
8. Women of childbearing potential must agree to use an adequate method of contraception during the trial and for 60 days after the end-of-trial visit. Adequate methods of contraception include intrauterine device or hormonal contraception (oral contraceptive pill, depot injections or implant, transdermal depot patch or vaginal ring). To be considered sterilised or infertile, females must have undergone surgical sterilisation (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be post-menopausal (defined as at least 12 months amenorrhoea and confirmed with follicle-stimulating hormone \[FSH\] test)

Exclusion Criteria

1. Pregnancy or lactation
2. Positive results on the human immunodeficiency virus (HIV), hepatitis B and/or C tests
3. A history of clinically significant intestinal adhesions and/or chronic abdominal pain
4. Require chronic systemic narcotics for treatment of pain that exceeds an amount corresponding to 80 mg of morphine per day
5. History of cancer or clinically significant lymphoproliferative disease within ≤5 years, except for adequately treated basal cell skin cancer
6. History of gallstone within the past 3 years. Gallstones with subsequent cholecystectomy to resolve the issues is acceptable
7. Inflammatory bowel disease (IBD) patients who have NOT been on a stable drug treatment regimen for at least the past 4 weeks
8. Evidence of active IBD in the past 12 weeks
9. Visible blood in the stool within the last 3 months
10. Catheter sepsis experienced within the last 3 months
11. Decompensated heart failure (New York Heart Association \[NYHA\] class III-IV) and/or known coronary heart disease defined as unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening
12. Radiation enteritis, scleroderma or other condition of intestinal dysmotility, coeliac disease, refractory or tropical sprue
13. History of alcohol and/or drug abuse within the last 12 months
14. Inadequate hepatic function as defined by: bilirubin \>upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) \>2.0 × ULN; alkaline phosphatase (ALP) \>2.5 × ULN; or international normalised ratio (INR) \>1.5 × ULN
15. Inadequate renal function as defined by serum creatinine or blood urea nitrogen \>2.5 × ULN
16. Unplanned hospitalisation of \>24 hours duration within 1 month before the screening visit
17. Systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, infliximab or other biologic therapy/immune modifiers within 30 days of screening
18. Any use of growth hormone, glutamine or growth factors such as native glucagon-like peptide 2 (GLP 2) or GLP 2 analogue within the last 3 months
19. Any use of antibiotics within the last 30 days
20. Participation in another clinical trial within the last 3 months and during this trial
21. Previously been randomised in this trial
22. Loss of blood or donation of blood or plasma \>500 mL within 3 months prior to screening
23. Patient not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements
24. For any other reason judged not eligible by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No